Clincosm LogoSign in Get a demo

hormone receptor positive tumor

Showing 1 - 20 of 20
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

Not yet recruiting
  • Breast Cancer
  • +3 more
  • (no location specified)
Aug 4, 2023

PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer Trial (RLY-5836, Fulvestrant, Palbociclib)

Not yet recruiting
  • PIK3CA Mutation
  • +7 more
  • (no location specified)
Mar 7, 2023

Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor Trial (INX-315)

Not yet recruiting
  • Breast Cancer
  • +8 more
  • (no location specified)
Feb 9, 2023

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG

Recruiting
  • Breast Neoplasms
  • +10 more
  • Standard Therapy
  • +32 more
  • Birmingham, Alabama
  • +35 more
Nov 17, 2022

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor Trial in Durham (Abemaciclib,

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Durham, North Carolina
    Duke University Medical Center
Jun 7, 2022

Breast Cancer, Hormone Receptor Positive Tumor Trial in Tampa (Durvalumab, Anastrozole 1mg, Letrozole 2.5mg)

Terminated
Has Results
  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
May 27, 2022

Breast Cancer, Hormone Receptor Positive Tumor Trial in Germany (3 weeks Dose Induction of Everolimus, 3 weeks Conventional

Completed
  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • 3 weeks Dose Induction of Everolimus
  • +3 more
  • Neu Isenburg, Hessen, Germany
  • +13 more
Feb 22, 2022

Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer Trial in Germany (Ribociclib and aromatase

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Ribociclib and aromatase inhibitor or fulvestrant
  • Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
  • Ravensburg, Baden-Wuerttemberg, Germany
  • +26 more
Dec 1, 2021

Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Germany

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Aachen, Germany
  • +69 more
Dec 1, 2021

Breast Tumor Female, Stage I Breast Cancer, Stage II Breast Cancer Trial in L'Hospitalet De Llobregat (Denosumab 120 MG/1.7 ML

Active, not recruiting
  • Breast Neoplasm Female
  • +4 more
  • Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
  • L'Hospitalet De Llobregat, Barcelona, Spain
    Institut Català d'Oncologia - L'Hospitalet
Nov 2, 2021

Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor Trial in Indianapolis, Winston-Salem

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Indianapolis, Indiana
  • +1 more
Sep 28, 2021

Early-stage Breast Cancer, Hormone Receptor Positive Tumor Trial in Sydney (Letrozole, Letrozole and Prometrium, Tamoxifen and

Recruiting
  • Early-stage Breast Cancer
  • Hormone Receptor Positive Tumor
  • Sydney, New South Wales, Australia
    St Vincent's Hospital
Sep 23, 2021

Breast Cancer Female, Hormone Receptor Positive Tumor Trial in Vancouver (Tamoxifen Citrate)

Recruiting
  • Breast Cancer Female
  • Hormone Receptor Positive Tumor
  • Tamoxifen Citrate
  • Vancouver, British Columbia, Canada
    BC Cancer
Dec 7, 2020

Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor Trial in Stockholm (Tamoxifen or Aromatase Inhibitor or Aromatase

Active, not recruiting
  • Early-Stage Breast Carcinoma
  • Hormone Receptor Positive Tumor
  • Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin
  • Palbociclib
  • Stockholm, Sweden
    Department of Oncology, Karolinska University Hospital
Jul 5, 2020

Breast Cancer, Hormone Receptor Positive Tumor, Arthralgia Trial in Florence (OPERA)

Completed
  • Breast Cancer
  • +2 more
  • OPERA
  • Florence, Italy
    Azienda Ospedaliero Universitaria Careggi
Nov 11, 2019

Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Tumor of Breast Trial in Fuzhou

Not yet recruiting
  • Breast Cancer Female
  • +5 more
  • Fuzhou, Fujian, China
    Fuzhou general hospital
Sep 11, 2019

Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Tumor of Breast Trial (Pyrotinib,

Not yet recruiting
  • Breast Cancer Female
  • +5 more
  • (no location specified)
Apr 9, 2019

Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor Trial in Italy (Everolimus, Exemestane, Fulvestrant)

Unknown status
  • Metastatic Breast Cancer
  • +4 more
  • Asti, Italy
  • +40 more
Jun 14, 2016